STOCK TITAN

Outset Medical, Inc. - OM STOCK NEWS

Welcome to our dedicated page for Outset Medical news (Ticker: OM), a resource for investors and traders seeking the latest updates and insights on Outset Medical stock.

Outset Medical, Inc. (symbol: OM) is a pioneering medical technology company committed to revolutionizing the dialysis experience. The company’s primary product, Tablo, is an innovative dialysis machine designed to simplify and streamline the process of Renal Replacement Therapy. By focusing on a patient-centric approach, Outset Medical places patient care, ease of use, and cost-efficiency at the forefront of its operations.

The Tablo dialysis system is built with a user-friendly touchscreen display that offers step-by-step visual and conversational instructions, making it accessible to both patients and caregivers, regardless of their experience level. This intuitive design dramatically reduces the complexity and cost associated with traditional dialysis treatments. Tablo can be used across various settings, including hospitals, chronic care dialysis clinics, and at home, making it a versatile solution for renal care.

Outset Medical’s mission is to improve the care experience for patients, families, providers, and physicians, while also enhancing cost-efficiencies for healthcare providers. The company achieves this by combining expertise from different healthcare fields, fostering an environment of cross-disciplinary innovation. This approach has led to significant advancements in dialysis technology and patient care.

Recent achievements include regulatory approvals and partnerships aimed at expanding Tablo’s reach and improving its functionalities. Financially, Outset Medical has shown robust growth, supported by a dedicated team of professionals and continuous innovation in their product offerings. The company's efforts are geared towards giving people their time back by reducing the dialysis process's complexity and duration.

Stay updated with the latest developments and news about Outset Medical, Inc. to learn how this industry leader is transforming renal care.

Rhea-AI Summary
Outset Medical and U.S. Renal Care have announced a multi-year agreement to accelerate home dialysis across the U.S. The agreement aims to provide patients with innovative home dialysis using the Tablo Hemodialysis System. Studies show that home dialysis can improve the mental and physical health of patients with end-stage kidney disease. Only 3% of the ESKD population currently performs home hemodialysis due to historical complexities. The partnership allows U.S. Renal Care to offer the Tablo system in 33 states, making dialysis more accessible and convenient for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
none
-
Rhea-AI Summary
Outset Medical partners with American Nephrology Nurses Association to support nephrology nursing and patient care. The collaboration aims to empower and educate nephrology nurses, enhancing patient outcomes in kidney disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
partnership
-
Rhea-AI Summary
Outset Medical, Inc. (OM) appoints medical technology veteran Brent D. Lang to its board of directors. Mr. Lang brings extensive healthcare expertise, including growing software-enabled business models. Katie M. Szyman steps down to prepare for a new role. Mr. Lang's background in leadership positions at Vocera and other companies makes him a valuable addition to the Outset board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.7%
Tags
management
Rhea-AI Summary
Outset Medical, Inc. (OM) will present at the 44th annual TD Cowen Health Care conference to showcase their innovative dialysis technology. The presentation will be on March 5, 2024, at 1:30 p.m. Eastern time. Investors can access the webcast on the Outset website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
conferences
-
Rhea-AI Summary
Outset Medical, Inc. (OM) reported fourth-quarter revenue of $30.5 million, with a 13% increase in 2023 revenue compared to 2022. The company achieved a 900 basis point increase in gross margin, reaching 25.3% in Q4. Outset's recurring revenue exceeded 50% of total revenue, with a Tablo installed base of 5,350 consoles. Despite a decrease in Q4 revenue, there was growth in service and other revenue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.23%
Tags
-
Rhea-AI Summary
Rollins, Inc. announces the nomination of Dale Jones for election to the Board of Directors at the 2024 Annual Meeting, while Lead Director Jerry Nix is set to retire. Dale Jones, currently the CEO of MagnaVista Partners, has extensive experience in leadership development consulting. Jerry Nix, who has been the Lead Director since 2021, will retire post the annual meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
management
Rhea-AI Summary
Outset Medical, Inc. (OM) will release financial results for Q4 and full-year 2023 on February 21, 2024. Leslie Trigg, CEO, and Nabeel Ahmed, CFO, will host a conference call to discuss financial and operating results. The conference call will be available via webcast on the 'Investors' section of the Outset website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.76%
Tags
conferences earnings
-
Rhea-AI Summary
Outset Medical, Inc. (OM) reported unaudited revenue for Q4 and fiscal year ended December 31, 2023, with revenue totaling $30.5 million in Q4 and $130 million for the year, a 13% increase from 2022. The period-end installed base increased 34% year-over-year to approximately 5,350 Tablo Hemodialysis Systems, with consumable revenue growing nearly 50% year-over-year. Outset's cash position is now approximately $270 million. 2024 revenue is expected to be between $145 million to $153 million, growing 12% to 18% over unaudited revenue for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.41%
Tags
none
-
Rhea-AI Summary
Outset Medical, Inc. (OM) to present at J.P. Morgan Healthcare conference on January 8, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
conferences
Rhea-AI Summary
Outset Medical, Inc. (OM) to participate in virtual panel discussion at BofA Securities Home Care Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
conferences

FAQ

What is the current stock price of Outset Medical (OM)?

The current stock price of Outset Medical (OM) is $0.7257 as of November 20, 2024.

What is the market cap of Outset Medical (OM)?

The market cap of Outset Medical (OM) is approximately 39.5M.

What is Outset Medical, Inc.?

Outset Medical, Inc. is a medical technology company focused on innovating dialysis treatment with its Tablo dialysis machine.

What product does Outset Medical offer?

Outset Medical offers the Tablo dialysis machine, designed to simplify and reduce the cost and complexity of dialysis.

How does the Tablo dialysis system work?

Tablo features a touchscreen display with step-by-step visual and conversational instructions, making it easy to use for patients and caregivers.

In what settings can Tablo be used?

Tablo can be used in hospitals, chronic care dialysis clinics, and at home.

What is the company's main mission?

Outset Medical aims to improve the care experience and cost-efficiency for patients, families, providers, and physicians.

Who can use the Tablo machine?

Tablo is designed to be user-friendly, making it accessible for both new and experienced patients and caregivers.

What is unique about the Tablo machine?

Tablo offers a simple, user-friendly interface with step-by-step instructions, reducing the complexity of dialysis treatments.

How does Outset Medical foster innovation?

Outset Medical combines expertise from various healthcare fields to drive cross-disciplinary innovation in dialysis technology.

What recent achievements does Outset Medical have?

Outset Medical has achieved regulatory approvals and formed partnerships to expand the reach and functionalities of the Tablo machine.

How has Outset Medical performed financially?

Outset Medical has shown robust financial growth, supported by continuous innovation and a dedicated professional team.

Outset Medical, Inc.

Nasdaq:OM

OM Rankings

OM Stock Data

39.46M
51.38M
2.13%
55.13%
6.37%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
SAN JOSE